Hydroxychloroquine and COVID-19.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32295814.
- Also identified by DOI 10.1136/postgradmedj-2020-137785 and PMC identifier 10016880.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hydroxychloroquine and chloroquine are medications that have been used for a long time. Their most common use is for the treatment and prophylaxis of malaria. However, these antimalarial drugs are known to also have anti-inflammatory and antiviral effects and are used for several chronic diseases such as systemic lupus erythematosus with low adverse effects. The antiviral action of hydroxychloroquine and chloroquine has been a point of interest to different researchers due to its mechanism of action. Several in vitro studies have proven their effectiveness on severe acute respiratory syndrome virus and currently both in vitro and in vivo studies have been conducted on 2019 novel coronavirus (covid-19). The purpose of this article is to review the history and mechanism of actions of these drugs and the potential use they can have on the current covid-19 pandemic.
Medical subject headings
- Antimalarials
- Betacoronavirus
- Coronavirus Infections
- Hydroxychloroquine
- Pneumonia, Viral